260 related articles for article (PubMed ID: 23828115)
1. Prediction of pseudoprogression in patients with glioblastomas using the initial and final area under the curves ratio derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging.
Suh CH; Kim HS; Choi YJ; Kim N; Kim SJ
AJNR Am J Neuroradiol; 2013 Dec; 34(12):2278-86. PubMed ID: 23828115
[TBL] [Abstract][Full Text] [Related]
2. Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options.
Heo YJ; Kim HS; Park JE; Choi CG; Kim SJ
PLoS One; 2015; 10(8):e0136380. PubMed ID: 26296086
[TBL] [Abstract][Full Text] [Related]
3. True progression versus pseudoprogression in the treatment of glioblastomas: a comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis.
Song YS; Choi SH; Park CK; Yi KS; Lee WJ; Yun TJ; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Jahng GH; Chang KH
Korean J Radiol; 2013; 14(4):662-72. PubMed ID: 23901325
[TBL] [Abstract][Full Text] [Related]
4. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
[TBL] [Abstract][Full Text] [Related]
5. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912
[TBL] [Abstract][Full Text] [Related]
7. Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas.
Baek HJ; Kim HS; Kim N; Choi YJ; Kim YJ
Radiology; 2012 Sep; 264(3):834-43. PubMed ID: 22771885
[TBL] [Abstract][Full Text] [Related]
8. Recurrent glioblastoma: optimum area under the curve method derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging.
Chung WJ; Kim HS; Kim N; Choi CG; Kim SJ
Radiology; 2013 Nov; 269(2):561-8. PubMed ID: 23878286
[TBL] [Abstract][Full Text] [Related]
9. Incorporating diffusion- and perfusion-weighted MRI into a radiomics model improves diagnostic performance for pseudoprogression in glioblastoma patients.
Kim JY; Park JE; Jo Y; Shim WH; Nam SJ; Kim JH; Yoo RE; Choi SH; Kim HS
Neuro Oncol; 2019 Feb; 21(3):404-414. PubMed ID: 30107606
[TBL] [Abstract][Full Text] [Related]
10. Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy.
Nam JG; Kang KM; Choi SH; Lim WH; Yoo RE; Kim JH; Yun TJ; Sohn CH
AJNR Am J Neuroradiol; 2017 Dec; 38(12):2243-2250. PubMed ID: 29074633
[TBL] [Abstract][Full Text] [Related]
11. Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation.
Yoon RG; Kim HS; Paik W; Shim WH; Kim SJ; Kim JH
Eur Radiol; 2017 Jan; 27(1):255-266. PubMed ID: 27048531
[TBL] [Abstract][Full Text] [Related]
12. Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI.
Wang S; Martinez-Lage M; Sakai Y; Chawla S; Kim SG; Alonso-Basanta M; Lustig RA; Brem S; Mohan S; Wolf RL; Desai A; Poptani H
AJNR Am J Neuroradiol; 2016 Jan; 37(1):28-36. PubMed ID: 26450533
[TBL] [Abstract][Full Text] [Related]
13. Differentiation of tumor progression from pseudoprogression in patients with posttreatment glioblastoma using multiparametric histogram analysis.
Cha J; Kim ST; Kim HJ; Kim BJ; Kim YK; Lee JY; Jeon P; Kim KH; Kong DS; Nam DH
AJNR Am J Neuroradiol; 2014 Jul; 35(7):1309-17. PubMed ID: 24676005
[TBL] [Abstract][Full Text] [Related]
14. Glioma: Application of histogram analysis of pharmacokinetic parameters from T1-weighted dynamic contrast-enhanced MR imaging to tumor grading.
Jung SC; Yeom JA; Kim JH; Ryoo I; Kim SC; Shin H; Lee AL; Yun TJ; Park CK; Sohn CH; Park SH; Choi SH
AJNR Am J Neuroradiol; 2014 Jun; 35(6):1103-10. PubMed ID: 24384119
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of primary central nervous system lymphomas from high-grade gliomas by rCBV and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.
Xing Z; You RX; Li J; Liu Y; Cao DR
Clin Neuroradiol; 2014 Dec; 24(4):329-36. PubMed ID: 23994941
[TBL] [Abstract][Full Text] [Related]
16. Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility.
Kim HS; Goh MJ; Kim N; Choi CG; Kim SJ; Kim JH
Radiology; 2014 Dec; 273(3):831-43. PubMed ID: 24885857
[TBL] [Abstract][Full Text] [Related]
17. Support vector machine multiparametric MRI identification of pseudoprogression from tumor recurrence in patients with resected glioblastoma.
Hu X; Wong KK; Young GS; Guo L; Wong ST
J Magn Reson Imaging; 2011 Feb; 33(2):296-305. PubMed ID: 21274970
[TBL] [Abstract][Full Text] [Related]
18. Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.
Lee WJ; Choi SH; Park CK; Yi KS; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH
Acad Radiol; 2012 Nov; 19(11):1353-61. PubMed ID: 22884399
[TBL] [Abstract][Full Text] [Related]
19. Prediction of pseudoprogression in post-treatment glioblastoma using dynamic susceptibility contrast-derived oxygenation and microvascular transit time heterogeneity measures.
Park JE; Kim HS; Kim N; Borra R; Mouridsen K; Hansen MB; Kim YH; Hong CK; Kim JH
Eur Radiol; 2024 May; 34(5):3061-3073. PubMed ID: 37848773
[TBL] [Abstract][Full Text] [Related]
20. Detection of Local Tumor Recurrence After Definitive Treatment of Head and Neck Squamous Cell Carcinoma: Histogram Analysis of Dynamic Contrast-Enhanced T1-Weighted Perfusion MRI.
Choi SH; Lee JH; Choi YJ; Park JE; Sung YS; Kim N; Baek JH
AJR Am J Roentgenol; 2017 Jan; 208(1):42-47. PubMed ID: 27680294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]